6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contactJanssen	NN	contactjanssen	contactjanssen	contactjanssen	N	O
Biotech	NNP	biotech	biotech	biotech	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
JANSSEN	NNP	janssen	janssen	janssen	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
526	CD	526	526	526	N	O
-	:	-	-	-	N	O
7736	CD	7736	7736	7736	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
one	CD	one	one	one	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
controlled	VBD	controlled	controlled	control	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RA	NNP	ra	ra	ra	Y	O
receiving	VBG	receiving	receiving	receiv	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
by	IN	by	by	by	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
infusion	NN	infusion	infusion	infus	Y	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
protocol	NN	protocol	protocol	protocol	N	O
included	VBD	included	included	includ	N	O
provisions	NNS	provisions	provision	provis	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
placebo	NN	placebo	placebo	placebo	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
16	CD	16	16	16	N	O
or	CC	or	or	or	N	O
Week	$	week	week	week	N	O
24	CD	24	24	24	N	O
either	CC	either	either	either	N	O
by	IN	by	by	by	N	O
patient	JJ	patient	patient	patient	N	O
response	NN	response	response	respons	N	O
(	(	(	(	(	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
disease	NN	disease	disease	diseas	N	O
activity	NN	activity	activity	activ	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
by	IN	by	by	by	N	O
design	NN	design	design	design	N	O
,	,	,	,	,	N	O
so	IN	so	so	so	N	O
that	DT	that	that	that	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
cannot	NN	cannot	cannot	cannot	N	O
always	RB	always	always	alway	N	O
be	VB	be	be	be	N	O
unambiguously	RB	unambiguously	unambiguously	unambigu	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
given	VBN	given	given	given	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Comparisons	NNS	comparisons	comparison	comparison	N	O
between	IN	between	between	between	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
were	VBD	were	were	were	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
included	VBD	included	included	includ	N	O
197	CD	197	197	197	N	O
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
463	CD	463	463	463	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
which	WDT	which	which	which	N	O
includes	VBZ	includes	includes	includ	N	O
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
switched	VBD	switched	switched	switch	N	O
to	TO	to	to	to	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
through	IN	through	through	through	N	O
Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
was	VBD	was	wa	wa	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
for	IN	for	for	for	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
through	IN	through	through	through	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
6.5%	CD	6.5%	6.5%	6.5%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
7.6%	CD	7.6%	7.6%	7.6%	N	O
of	IN	of	of	of	N	O
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
included	JJ	included	included	includ	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cellulitis	NN	cellulitis	cellulitis	cellul	Y	B-AdverseReaction
,	,	,	,	,	N	O
abscess	NN	abscess	abscess	abscess	Y	B-AdverseReaction
,	,	,	,	,	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
included	VBD	included	included	includ	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
and	CC	and	and	and	N	O
extrapulmonary	JJ	extrapulmonary	extrapulmonary	extrapulmonari	N	B-AdverseReaction
TB	NNP	tb	tb	tb	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
cases	NNS	cases	case	case	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
countries	NNS	countries	country	countri	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
incidence	NN	incidence	incidence	incid	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
TB	NNP	tb	tb	tb	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
through	IN	through	through	through	N	O
Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
27%	CD	27%	27%	27%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
24%	CD	24%	24%	24%	N	O
of	IN	of	of	of	N	O
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
of	IN	of	of	of	N	O
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Through	IN	through	through	through	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	NN	up	up	up	N	O
was	VBD	was	wa	wa	N	O
2.2	CD	2.2	2.2	2.2	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
0.61	CD	0.61	0.61	0.61	N	O
,	,	,	,	,	N	O
5.71	CD	5.71	5.71	5.71	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0.00	CD	0.00	0.00	0.00	N	O
,	,	,	,	,	N	O
3.79	CD	3.79	3.79	3.79	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
958	CD	958	958	958	N	O
total	JJ	total	total	total	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RB	up	up	up	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
92	CD	92	92	92	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
4.07	CD	4.07	4.07	4.07	N	O
(	(	(	(	(	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
2.90	CD	2.90	2.90	2.90	N	O
,	,	,	,	,	N	O
5.57	CD	5.57	5.57	5.57	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
active	JJ	active	active	activ	N	B-AdverseReaction
TB	NNP	tb	tb	tb	Y	I-AdverseReaction
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
was	VBD	was	wa	wa	N	O
0.31	CD	0.31	0.31	0.31	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
0.06	CD	0.06	0.06	0.06	N	O
;	:	;	;	;	N	O
0.92	CD	0.92	0.92	0.92	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
was	VBD	was	wa	wa	N	O
0.42	CD	0.42	0.42	0.42	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
0.11	CD	0.11	0.11	0.11	N	O
,	,	,	,	,	N	O
1.07	CD	1.07	1.07	1.07	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	O

One	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
malignancy	NN	malignancy	malignancy	malign	N	B-AdverseReaction
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
NMSC	NNP	nmsc	nmsc	nmsc	N	B-AdverseReaction
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
through	IN	through	through	through	N	O
Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
portions	NNS	portions	portion	portion	N	O
through	IN	through	through	through	N	O
approximately	RB	approximately	approximately	approxim	N	O
92	CD	92	92	92	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
NMSC	NNP	nmsc	nmsc	nmsc	N	B-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
0.31	CD	0.31	0.31	0.31	N	O
(	(	(	(	(	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
0.06	CD	0.06	0.06	0.06	N	O
,	,	,	,	,	N	O
0.92	CD	0.92	0.92	0.92	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
NMSC	NNP	nmsc	nmsc	nmsc	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
0.1	CD	0.1	0.1	0.1	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
0.00	CD	0.00	0.00	0.00	N	O
,	,	,	,	,	N	O
0.58	CD	0.58	0.58	0.58	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Liver	NNP	liver	liver	liver	N	O
Enzyme	NNP	enzyme	enzyme	enzym	N	O
Elevations	NNP	elevations	elevation	elev	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
liver	JJ	liver	liver	liver	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
through	IN	through	through	through	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevations	VBZ	elevations	elevation	elev	N	I-AdverseReaction
5	CD	5	5	5	N	B-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0%	CD	0%	0%	0%	N	O
of	IN	of	of	of	N	O
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
3	CD	3	3	3	N	B-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
of	IN	of	of	of	N	O
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Since	IN	since	since	sinc	N	O
many	JJ	many	many	mani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trial	NN	trial	trial	trial	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
taking	VBG	taking	taking	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
cause	VBP	cause	cause	caus	N	O
liver	JJ	liver	liver	liver	N	O
enzyme	JJ	enzyme	enzyme	enzym	N	O
elevations	NNS	elevations	elevation	elev	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
nonsteroidal	JJ	nonsteroidal	nonsteroidal	nonsteroid	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
drugs	NNS	drugs	drug	drug	N	O
[	VBP	[	[	[	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
]	NNP	]	]	]	N	O
,	,	,	,	,	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
[	NNP	[	[	[	N	O
MTX	NNP	mtx	mtx	mtx	N	O
]	NNP	]	]	]	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
isoniazid	VB	isoniazid	isoniazid	isoniazid	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
and	CC	and	and	and	N	O
liver	RB	liver	liver	liver	N	O
enzyme	JJ	enzyme	enzyme	enzym	N	O
elevation	NN	elevation	elevation	elev	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
clear	JJ	clear	clear	clear	N	O
.	.	.	.	.	N	O

Autoimmune	NNP	autoimmune	autoimmune	autoimmun	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Autoantibodies	NNS	autoantibodies	autoantibody	autoantibodi	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
formation	NN	formation	formation	format	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
autoantibodies	NNS	autoantibodies	autoantibody	autoantibodi	N	I-AdverseReaction
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
rarely	RB	rarely	rarely	rare	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
lupus	JJ	lupus	lupus	lupu	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
20	CD	20	20	20	N	O
in	IN	in	in	in	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
17%	CD	17%	17%	17%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
control	NN	control	control	control	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
newly	RB	newly	newly	newli	N	B-AdverseReaction
ANA	NNP	ana	ana	ana	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
positive	JJ	positive	positive	posit	N	I-AdverseReaction
(	(	(	(	(	N	O
at	IN	at	at	at	N	B-Severity
titers	NNS	titers	titer	titer	N	I-Severity
of	IN	of	of	of	N	I-Severity
1	CD	1	1	1	N	I-Severity
:	:	:	:	:	N	I-Severity
160	CD	160	160	160	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patient	JJ	patient	patient	patient	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	B-Negation
control	NN	control	control	control	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
newly	RB	newly	newly	newli	N	B-AdverseReaction
positive	JJ	positive	positive	posit	N	I-AdverseReaction
anti	SYM	anti	anti	anti	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
dsDNA	NN	dsdna	dsdna	dsdna	N	I-AdverseReaction
antibodies	NNS	antibodies	antibody	antibodi	N	I-AdverseReaction
.	.	.	.	.	N	O

Administration	NN	administration	administration	administr	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
through	IN	through	through	through	N	O
Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
infusions	NNS	infusions	infusion	infus	N	O
were	VBD	were	were	were	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
infusions	NNS	infusions	infusion	infus	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
infusion	NN	infusion	infusion	infus	Y	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
serious	JJ	serious	serious	seriou	N	B-Severity
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

Antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
in	IN	in	in	in	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
following	VBG	following	following	follow	N	O
IV	NNP	iv	iv	iv	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
MTX	NNP	mtx	mtx	mtx	N	O
through	IN	through	through	through	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
of	IN	of	of	of	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
golimumab	VB	golimumab	golimumab	golimumab	N	O
had	VBD	had	had	had	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
an	DT	an	an	an	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
cell	NN	cell	cell	cell	N	O
-	:	-	-	-	N	O
based	VBN	based	based	base	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
small	JJ	small	small	small	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
limits	VBZ	limits	limit	limit	N	O
the	DT	the	the	the	N	O
ability	NN	ability	ability	abil	N	O
to	TO	to	to	to	N	O
draw	VB	draw	draw	draw	N	O
definitive	JJ	definitive	definitive	definit	N	O
conclusions	NNS	conclusions	conclusion	conclus	N	O
regarding	VBG	regarding	regarding	regard	N	O
the	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
golimumab	VB	golimumab	golimumab	golimumab	N	O
and	CC	and	and	and	N	O
clinical	JJ	clinical	clinical	clinic	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
or	CC	or	or	or	N	O
safety	NN	safety	safety	safeti	N	O
measures	NNS	measures	measure	measur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
above	IN	above	above	abov	N	O
reflect	VBP	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
test	NN	test	test	test	N	O
results	NNS	results	result	result	N	O
were	VBD	were	were	were	N	O
considered	VBN	considered	considered	consid	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
ELISA	NNP	elisa	elisa	elisa	Y	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
ELISA	NNP	elisa	elisa	elisa	Y	O
assay	NN	assay	assay	assay	N	O
is	VBZ	is	is	is	N	O
subject	JJ	subject	subject	subject	N	O
to	TO	to	to	to	N	O
interference	VB	interference	interference	interfer	N	O
by	IN	by	by	by	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
present	JJ	present	present	present	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
and	CC	and	and	and	N	O
thus	RB	thus	thus	thu	N	O
the	DT	the	the	the	N	O
results	NNS	results	result	result	N	O
are	VBP	are	are	are	N	O
an	DT	an	an	an	N	O
underestimate	NN	underestimate	underestimate	underestim	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
product	NN	product	product	product	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
in	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
summarizes	VBZ	summarizes	summarizes	summar	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
MTX	NNP	mtx	mtx	mtx	N	O
group	NN	group	group	group	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
MTX	NNP	mtx	mtx	mtx	N	O
group	NN	group	group	group	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
through	IN	through	through	through	N	O
Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	NNP	reported	reported	report	N	O
by	IN	by	by	by	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
through	IN	through	through	through	N	O
Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
MTX	NNP	mtx	mtx	mtx	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
MTX	NNP	mtx	mtx	mtx	N	O

Patients	NNS	patients	patient	patient	N	O

treated	VBD	treated	treated	treat	N	O
197	CD	197	197	197	N	O
463	CD	463	463	463	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NN	reaction	reaction	reaction	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
laryngitis	NN	laryngitis	laryngitis	laryng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
)	)	)	)	)	N	O
12%	CD	12%	12%	12%	N	O
13%	CD	13%	13%	13%	N	O

Viral	JJ	viral	viral	viral	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
and	CC	and	and	and	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
)	)	)	)	)	N	O
3%	CD	3%	3%	3%	N	O
4%	CD	4%	4%	4%	N	O

Bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
0%	CD	0%	0%	0%	N	O
1%	CD	1%	1%	1%	N	O

Bronchitis	NNP	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
3%	CD	3%	3%	3%	N	O

Vascular	JJ	vascular	vascular	vascular	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
2%	CD	2%	2%	2%	N	O
3%	CD	3%	3%	3%	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
3%	CD	3%	3%	3%	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O

Blood	NN	blood	blood	blood	N	B-AdverseReaction
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
0%	CD	0%	0%	0%	N	O
1%	CD	1%	1%	1%	N	O

Other	JJ	other	other	other	N	O
and	CC	and	and	and	N	O
less	RBR	less	le	less	N	O
common	JJ	common	common	common	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O

Adverse	NN	adverse	adverse	advers	N	O

drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
appear	VB	appear	appear	appear	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
that	IN	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
through	IN	through	through	through	N	O
Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
that	WDT	that	that	that	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
appear	VB	appear	appear	appear	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
section	NN	section	section	section	N	O
included	VBD	included	included	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
events	NNS	events	event	event	N	O
listed	VBN	listed	listed	list	N	O
by	IN	by	by	by	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
:	:	:	:	:	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
Superficial	JJ	superficial	superficial	superfici	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
abscess	NN	abscess	abscess	abscess	Y	B-AdverseReaction
,	,	,	,	,	N	O
lower	JJR	lower	lower	lower	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyelonephritis	NN	pyelonephritis	pyelonephritis	pyelonephr	Y	B-AdverseReaction

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
Alanine	NNP	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction

6.2	CD	6.2	6.2	6.2	N	O
Post	NNP	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
Experience	NN	experience	experience	experi	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
experience	NN	experience	experience	experi	N	O
available	JJ	available	available	avail	N	O
for	IN	for	for	for	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
formulation	NN	formulation	formulation	formul	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
golimumab	VB	golimumab	golimumab	golimumab	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Neoplasm	NNP	neoplasm	neoplasm	neoplasm	Y	O
Benign	NNP	benign	benign	benign	N	O
and	CC	and	and	and	N	O
Malignant	NNP	malignant	malignant	malign	N	O
:	:	:	:	:	N	O
Melanoma	NNP	melanoma	melanoma	melanoma	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
systemic	JJ	systemic	systemic	system	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
sarcoidosis	NN	sarcoidosis	sarcoidosis	sarcoidosi	Y	B-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Interstitial	NNP	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Skin	NNP	skin	skin	skin	N	B-AdverseReaction
exfoliation	NN	exfoliation	exfoliation	exfoli	Y	I-AdverseReaction
,	,	,	,	,	N	O
bullous	JJ	bullous	bullous	bullou	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
\n\n	VBP	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
SERIOUS	JJ	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
MALIGNANCY	NNP	malignancy	malignancy	malign	N	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
SERIOUS	JJ	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
MALIGNANCY	NNP	malignancy	malignancy	malign	N	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
EXCERPT	NNP	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
SERIOUS	JJ	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
MALIGNANCY	NNP	malignancy	malignancy	malign	N	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
sepsis	NN	sepsis	sepsis	sepsi	Y	I-AdverseReaction
,	,	,	,	,	N	O
invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
or	CC	or	or	or	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Perform	NNP	perform	perform	perform	N	O
test	NN	test	test	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
TB	NNP	tb	tb	tb	Y	O
;	:	;	;	;	N	O
if	IN	if	if	if	N	O
positive	JJ	positive	positive	posit	N	O
,	,	,	,	,	N	O
start	JJ	start	start	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
TB	NNP	tb	tb	tb	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
starting	VBG	starting	starting	start	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
active	JJ	active	active	activ	N	O
TB	NNP	tb	tb	tb	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
even	RB	even	even	even	N	O
if	IN	if	if	if	N	O
initial	JJ	initial	initial	initi	N	O
latent	NN	latent	latent	latent	N	O
TB	NNP	tb	tb	tb	Y	O
test	NN	test	test	test	N	O
is	VBZ	is	is	is	N	O
negative	JJ	negative	negative	neg	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

SERIOUS	NNP	serious	serious	seriou	N	O
INFECTIONS	NNP	infections	infection	infect	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Patients	NNP	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
these	DT	these	these	these	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
or	CC	or	or	or	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Reported	VBN	reported	reported	report	N	O
infections	NNS	infections	infection	infect	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
,	,	,	,	,	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Active	NNP	active	active	activ	N	B-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
latent	JJ	latent	latent	latent	N	I-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
frequently	RB	frequently	frequently	frequent	N	O
presented	VBN	presented	presented	present	N	O
with	IN	with	with	with	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	I-AdverseReaction
or	CC	or	or	or	N	O
extrapulmonary	JJ	extrapulmonary	extrapulmonary	extrapulmonari	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Test	NN	test	test	test	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
before	IN	before	before	befor	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
use	NN	use	use	use	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Initiate	NNP	initiate	initiate	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
coccidioidomycosis	NN	coccidioidomycosis	coccidioidomycosis	coccidioidomycosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
blastomycosis	NN	blastomycosis	blastomycosis	blastomycosi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
pneumocystosis	NN	pneumocystosis	pneumocystosis	pneumocystosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infections	NNS	infections	infection	infect	N	O
may	MD	may	may	may	N	O
present	VB	present	present	present	N	O
with	IN	with	with	with	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	O
,	,	,	,	,	N	O
rather	RB	rather	rather	rather	N	O
than	IN	than	than	than	N	O
localized	VBN	localized	localized	local	N	O
,	,	,	,	,	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Antigen	NNP	antigen	antigen	antigen	N	O
and	CC	and	and	and	N	O
antibody	NN	antibody	antibody	antibodi	N	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
negative	JJ	negative	negative	neg	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
empiric	JJ	empiric	empiric	empir	N	O
anti	NN	anti	anti	anti	N	O
-	:	-	-	-	N	O
fungal	JJ	fungal	fungal	fungal	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infections	NNS	infections	infection	infect	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
severe	JJ	severe	severe	sever	N	O
systemic	JJ	systemic	systemic	system	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

Bacterial	NNP	bacterial	bacterial	bacteri	N	B-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
infections	NNS	infections	infection	infect	N	I-AdverseReaction
due	JJ	due	due	due	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	I-AdverseReaction
pathogens	NNS	pathogens	pathogen	pathogen	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Legionella	NNP	legionella	legionella	legionella	N	I-AdverseReaction
and	CC	and	and	and	N	O
Listeria	NNP	listeria	listeria	listeria	N	I-AdverseReaction
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
or	CC	or	or	or	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
negative	JJ	negative	negative	neg	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

MALIGNANCY	NNP	malignancy	malignancy	malign	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
\n	CC	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
-	:	-	-	-	N	O
Do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
start	VB	start	start	start	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
during	IN	during	during	dure	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
an	DT	an	an	an	N	O
infection	NN	infection	infection	infect	Y	O
develops	VBZ	develops	develops	develop	N	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
carefully	RB	carefully	carefully	care	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
stop	VB	stop	stop	stop	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
if	IN	if	if	if	N	O
infection	NN	infection	infection	infect	Y	O
becomes	VBZ	becomes	becomes	becom	N	O
serious	JJ	serious	serious	seriou	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
-	:	-	-	-	N	O
For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
systemic	JJ	systemic	systemic	system	N	O
illness	NN	illness	illness	ill	N	O
on	IN	on	on	on	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
empiric	JJ	empiric	empiric	empir	N	O
antifungal	NN	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
reside	VBP	reside	reside	resid	N	O
in	IN	in	in	in	N	O
or	CC	or	or	or	N	O
travel	NN	travel	travel	travel	N	O
to	TO	to	to	to	N	O
regions	NNS	regions	region	region	N	O
where	WRB	where	where	where	N	O
mycoses	NNS	mycoses	mycoses	mycos	N	O
are	VBP	are	are	are	N	O
endemic	JJ	endemic	endemic	endem	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
reactivation	NN	reactivation	reactivation	reactiv	N	I-AdverseReaction
-	:	-	-	-	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
HBV	NNP	hbv	hbv	hbv	N	O
carriers	NNS	carriers	carrier	carrier	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
stop	VB	stop	stop	stop	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
and	CC	and	and	and	N	O
begin	VB	begin	begin	begin	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
viral	JJ	viral	viral	viral	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
-	:	-	-	-	N	O
More	JJR	more	more	more	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Heart	NNP	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
-	:	-	-	-	N	O
Worsening	NN	worsening	worsening	worsen	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
new	JJ	new	new	new	N	I-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Stop	NNP	stop	stop	stop	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
if	IN	if	if	if	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
occur	VBP	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Demyelinating	VBG	demyelinating	demyelinating	demyelin	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
or	CC	or	or	or	N	O
new	JJ	new	new	new	N	I-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
systemic	JJ	systemic	systemic	system	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Serious	JJ	serious	serious	seriou	N	O

Infections	NNS	infections	infection	infect	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
involving	VBG	involving	involving	involv	N	O
various	JJ	various	various	variou	N	O
organ	JJ	organ	organ	organ	N	O
systems	NNS	systems	system	system	N	O
and	CC	and	and	and	N	O
sites	NNS	sites	site	site	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	I-AdverseReaction
,	,	,	,	,	N	O
mycobacterial	JJ	mycobacterial	mycobacterial	mycobacteri	N	I-AdverseReaction
,	,	,	,	,	N	O
invasive	JJ	invasive	invasive	invas	N	I-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
parasitic	JJ	parasitic	parasitic	parasit	N	I-AdverseReaction
organisms	NNS	organisms	organism	organ	N	O
including	VBG	including	including	includ	N	O
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
blastomycosis	NN	blastomycosis	blastomycosis	blastomycosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
coccidioidomycosis	NN	coccidioidomycosis	coccidioidomycosis	coccidioidomycosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
legionellosis	NN	legionellosis	legionellosis	legionellosi	N	B-AdverseReaction
,	,	,	,	,	N	O
listeriosis	NN	listeriosis	listeriosis	listeriosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumocystosis	NN	pneumocystosis	pneumocystosis	pneumocystosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
frequently	RB	frequently	frequently	frequent	N	O
presented	VBN	presented	presented	present	N	O
with	IN	with	with	with	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	O
rather	RB	rather	rather	rather	N	O
than	IN	than	than	than	N	O
localized	JJ	localized	localized	local	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
and	CC	and	and	and	N	O
abatacept	NN	abatacept	abatacept	abatacept	N	O
or	CC	or	or	or	N	O
anakinra	NN	anakinra	anakinra	anakinra	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
infections	NNS	infections	infection	infect	N	O
;	:	;	;	;	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
and	CC	and	and	and	N	O
these	DT	these	these	these	N	O
biologic	JJ	biologic	biologic	biolog	N	O
products	NNS	products	product	product	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
,	,	,	,	,	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
clinically	RB	clinically	clinically	clinic	N	O
important	JJ	important	important	import	N	O
localized	VBN	localized	localized	local	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
morbid	NN	morbid	morbid	morbid	N	O
conditions	NNS	conditions	condition	condit	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
or	CC	or	or	or	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O

with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
or	CC	or	or	or	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
infection	NN	infection	infection	infect	Y	O
;	:	;	;	;	N	O

who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
;	:	;	;	;	N	O

with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
infection	NN	infection	infection	infect	Y	O
;	:	;	;	;	N	O

who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
resided	VBN	resided	resided	resid	N	O
or	CC	or	or	or	N	O
traveled	VBN	traveled	traveled	travel	N	O
in	IN	in	in	in	N	O
areas	NNS	areas	area	area	N	O
of	IN	of	of	of	N	O
endemic	JJ	endemic	endemic	endem	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
or	CC	or	or	or	N	O
endemic	JJ	endemic	endemic	endem	N	O
mycoses	NNS	mycoses	mycoses	mycos	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	O
,	,	,	,	,	N	O
coccidioidomycosis	NN	coccidioidomycosis	coccidioidomycosis	coccidioidomycosi	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
blastomycosis	NN	blastomycosis	blastomycosis	blastomycosi	Y	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O

with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Monitoring	VBG	monitoring	monitoring	monitor	N	O

Closely	RB	closely	closely	close	N	O

monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
perform	VB	perform	perform	perform	N	O
a	DT	a	a	a	N	O
prompt	NN	prompt	prompt	prompt	N	O
and	CC	and	and	and	N	O
complete	JJ	complete	complete	complet	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
workup	NN	workup	workup	workup	N	O
appropriate	NN	appropriate	appropriate	appropri	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
immunocompromised	JJ	immunocompromised	immunocompromised	immunocompromis	Y	O
patient	NN	patient	patient	patient	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
antimicrobial	JJ	antimicrobial	antimicrobial	antimicrobi	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
closely	RB	closely	closely	close	N	O
monitor	VB	monitor	monitor	monitor	N	O
them	PRP	them	them	them	N	O
.	.	.	.	.	N	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
or	CC	or	or	or	N	O
new	JJ	new	new	new	N	B-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
previously	RB	previously	previously	previous	N	O
received	VBN	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	NN	latent	latent	latent	N	O
or	CC	or	or	or	N	O
active	JJ	active	active	activ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
.	.	.	.	.	N	O

Evaluate	NN	evaluate	evaluate	evalu	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
and	CC	and	and	and	N	O
test	NN	test	test	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
assess	NN	assess	ass	assess	N	O
if	IN	if	if	if	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
is	VBZ	is	is	is	N	O
needed	VBN	needed	needed	need	N	O
;	:	;	;	;	N	O
An	DT	an	an	an	N	O
induration	NN	induration	induration	indur	Y	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mm	NN	mm	mm	mm	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
positive	JJ	positive	positive	posit	N	O
tuberculin	NN	tuberculin	tuberculin	tuberculin	N	O
skin	JJ	skin	skin	skin	N	O
test	NN	test	test	test	N	O
,	,	,	,	,	N	O
even	RB	even	even	even	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
previously	RB	previously	previously	previous	N	O
vaccinated	VBN	vaccinated	vaccinated	vaccin	N	O
with	IN	with	with	with	N	O
Bacille	NNP	bacille	bacille	bacil	N	O
Calmette	NNP	calmette	calmette	calmett	N	O
-	:	-	-	-	N	O
Guerin	NNP	guerin	guerin	guerin	N	O
(	(	(	(	(	N	O
BCG	NNP	bcg	bcg	bcg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
therapy	NN	therapy	therapy	therapi	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
past	JJ	past	past	past	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
latent	NN	latent	latent	latent	N	O
or	CC	or	or	or	N	O
active	JJ	active	active	activ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
an	DT	an	an	an	N	O
adequate	JJ	adequate	adequate	adequ	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
negative	JJ	negative	negative	neg	N	O
test	NN	test	test	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
but	CC	but	but	but	N	O
having	VBG	having	having	have	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Consultation	NN	consultation	consultation	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
with	IN	with	with	with	N	O
expertise	NN	expertise	expertise	expertis	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
to	TO	to	to	to	N	O
aid	NN	aid	aid	aid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
decision	NN	decision	decision	decis	N	O
whether	IN	whether	whether	whether	N	O
initiating	VBG	initiating	initiating	initi	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
therapy	NN	therapy	therapy	therapi	N	O
is	VBZ	is	is	is	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
individual	JJ	individual	individual	individu	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
active	JJ	active	active	activ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
formulation	NN	formulation	formulation	formul	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
including	VBG	including	including	includ	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
negative	JJ	negative	negative	neg	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
on	IN	on	on	on	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
differential	JJ	differential	differential	differenti	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
previously	RB	previously	previously	previous	N	O
or	CC	or	or	or	N	O
recently	RB	recently	recently	recent	N	O
traveled	VBD	traveled	traveled	travel	N	O
to	TO	to	to	to	N	O
countries	NNS	countries	country	countri	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
prevalence	NN	prevalence	prevalence	preval	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
close	JJ	close	close	close	N	O
contact	NN	contact	contact	contact	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
person	NN	person	person	person	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
.	.	.	.	.	N	O

Invasive	JJ	invasive	invasive	invas	N	O
Fungal	NNP	fungal	fungal	fungal	N	O
Infections	NNS	infections	infection	infect	N	O

If	IN	if	if	if	N	O
patients	NNS	patients	patient	patient	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
systemic	JJ	systemic	systemic	system	N	O
illness	NN	illness	illness	ill	N	O
and	CC	and	and	and	N	O
they	PRP	they	they	they	N	O
reside	VBP	reside	reside	resid	N	O
or	CC	or	or	or	N	O
travel	VBP	travel	travel	travel	N	O
in	IN	in	in	in	N	O
regions	NNS	regions	region	region	N	O
where	WRB	where	where	where	N	O
mycoses	NNS	mycoses	mycoses	mycos	N	O
are	VBP	are	are	are	N	O
endemic	JJ	endemic	endemic	endem	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infection	NN	infection	infection	infect	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
differential	JJ	differential	differential	differenti	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
empiric	JJ	empiric	empiric	empir	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
take	VB	take	take	take	N	O
into	IN	into	into	into	N	O
account	NN	account	account	account	N	O
both	CC	both	both	both	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
while	IN	while	while	while	N	O
a	DT	a	a	a	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
workup	NN	workup	workup	workup	N	O
is	VBZ	is	is	is	N	O
being	VBG	being	being	be	N	O
performed	VBN	performed	performed	perform	N	O
.	.	.	.	.	N	O

Antigen	NNP	antigen	antigen	antigen	N	O
and	CC	and	and	and	N	O
antibody	NN	antibody	antibody	antibodi	N	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
negative	JJ	negative	negative	neg	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
aid	NN	aid	aid	aid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
such	JJ	such	such	such	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
consultation	NN	consultation	consultation	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
with	IN	with	with	with	N	O
expertise	NN	expertise	expertise	expertis	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
Virus	NNP	virus	virus	viru	N	O
Reactivation	NNP	reactivation	reactivation	reactiv	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
(	(	(	(	(	N	O
HBV	NNP	hbv	hbv	hbv	N	I-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
carriers	NNS	carriers	carrier	carrier	N	O
(	(	(	(	(	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
surface	NN	surface	surface	surfac	N	O
antigen	RB	antigen	antigen	antigen	N	O
positive	JJ	positive	positive	posit	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
instances	NNS	instances	instance	instanc	N	O
,	,	,	,	,	N	O
HBV	NNP	hbv	hbv	hbv	N	B-AdverseReaction
reactivation	NN	reactivation	reactivation	reactiv	N	I-AdverseReaction
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
reports	NNS	reports	report	report	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
HBV	NNP	hbv	hbv	hbv	N	O
infection	NN	infection	infection	infect	Y	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
test	VBP	test	test	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
surface	NN	surface	surface	surfac	N	O
antigen	NN	antigen	antigen	antigen	N	O
,	,	,	,	,	N	O
consultation	NN	consultation	consultation	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
with	IN	with	with	with	N	O
expertise	NN	expertise	expertise	expertis	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
carriers	NNS	carriers	carrier	carrier	N	O
of	IN	of	of	of	N	O
HBV	NNP	hbv	hbv	hbv	N	O
.	.	.	.	.	N	O

Adequate	NNP	adequate	adequate	adequ	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
on	IN	on	on	on	N	O
whether	IN	whether	whether	whether	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
viral	JJ	viral	viral	viral	N	O
therapy	NN	therapy	therapy	therapi	N	O
can	MD	can	can	can	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
HBV	NNP	hbv	hbv	hbv	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
in	IN	in	in	in	N	O
HBV	NNP	hbv	hbv	hbv	N	O
carriers	NNS	carriers	carrier	carrier	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
carriers	NNS	carriers	carrier	carrier	N	O
of	IN	of	of	of	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
require	VB	require	require	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
clinical	JJ	clinical	clinical	clinic	N	O
and	CC	and	and	and	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
active	JJ	active	active	activ	N	O
HBV	NNP	hbv	hbv	hbv	N	O
infection	NN	infection	infection	infect	Y	O
throughout	IN	throughout	throughout	throughout	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
following	VBG	following	following	follow	N	O
termination	NN	termination	termination	termin	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
HBV	NNP	hbv	hbv	hbv	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
,	,	,	,	,	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
stopped	VBN	stopped	stopped	stop	N	O
and	CC	and	and	and	N	O
antiviral	JJ	antiviral	antiviral	antivir	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
supportive	JJ	supportive	supportive	support	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
resuming	VBG	resuming	resuming	resum	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
after	IN	after	after	after	N	O
HBV	NNP	hbv	hbv	hbv	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
controlled	VBN	controlled	controlled	control	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
prescribers	NNS	prescribers	prescribers	prescrib	N	O
should	MD	should	should	should	N	O
exercise	VB	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
considering	VBG	considering	considering	consid	N	O
resumption	NN	resumption	resumption	resumpt	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
situation	NN	situation	situation	situat	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	O
in	IN	in	in	in	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Patients	NNS	patients	patient	patient	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
among	IN	among	among	among	N	O
children	NNS	children	child	children	N	O
,	,	,	,	,	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
young	JJ	young	young	young	N	O
adults	NNS	adults	adult	adult	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocking	VBG	blocking	blocking	block	N	O
agents	NNS	agents	agent	agent	N	O
(	(	(	(	(	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
half	PDT	half	half	half	N	O
the	DT	the	the	the	N	O
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
lymphomas	JJ	lymphomas	lymphoma	lymphoma	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	B-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	I-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
cases	NNS	cases	case	case	N	O
represented	VBD	represented	represented	repres	N	O
a	DT	a	a	a	N	O
variety	NN	variety	variety	varieti	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
rare	JJ	rare	rare	rare	N	B-AdverseReaction
malignancies	NNS	malignancies	malignancy	malign	N	I-AdverseReaction
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
usually	RB	usually	usually	usual	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
usually	RB	usually	usually	usual	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
a	DT	a	a	a	N	O
median	NN	median	median	median	N	O
of	IN	of	of	of	N	O
30	CD	30	30	30	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
84	CD	84	84	84	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
receiving	VBG	receiving	receiving	receiv	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
variety	NN	variety	variety	varieti	N	O
of	IN	of	of	of	N	O
sources	NNS	sources	source	sourc	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
registries	NNS	registries	registry	registri	N	O
and	CC	and	and	and	N	O
spontaneous	JJ	spontaneous	spontaneous	spontan	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
reports	NNS	reports	report	report	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
under	IN	under	under	under	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O

The	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
treatment	NN	treatment	treatment	treatment	N	O
including	VBG	including	including	includ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
known	VBN	known	known	known	N	O
malignancy	NN	malignancy	malignancy	malign	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
a	DT	a	a	a	N	O
successfully	RB	successfully	successfully	success	N	O
treated	VBN	treated	treated	treat	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
skin	NN	skin	skin	skin	N	O
cancer	NN	cancer	cancer	cancer	Y	O
(	(	(	(	(	N	O
NMSC	NNP	nmsc	nmsc	nmsc	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
when	WRB	when	when	when	N	O
considering	VBG	considering	considering	consid	N	O
continuing	VBG	continuing	continuing	continu	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
malignancy	NN	malignancy	malignancy	malign	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
formulation	NN	formulation	formulation	formul	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
more	RBR	more	more	more	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
TNF	NNP	tnf	tnf	tnf	N	O
treatment	NN	treatment	treatment	treatment	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RA	NNP	ra	ra	ra	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
chronic	JJ	chronic	chronic	chronic	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
diseases	NNS	diseases	disease	diseas	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
highly	RB	highly	highly	highli	N	O
active	JJ	active	active	activ	N	O
disease	NN	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
chronic	JJ	chronic	chronic	chronic	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
immunosuppressant	VB	immunosuppressant	immunosuppressant	immunosuppress	N	O
therapies	NNS	therapies	therapy	therapi	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	B-Factor
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
several	JJ	several	several	sever	N	O
fold	NN	fold	fold	fold	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
even	RB	even	even	even	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocking	VBG	blocking	blocking	block	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
and	CC	and	and	and	N	O
chronic	JJ	chronic	chronic	chronic	N	B-AdverseReaction
leukemia	NN	leukemia	leukemia	leukemia	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
rheumatoid	JJ	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
indications	NNS	indications	indication	indic	N	O
.	.	.	.	.	N	O

Even	RB	even	even	even	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
rheumatoid	JJ	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
(	(	(	(	(	N	O
approximately	RB	approximately	approximately	approxim	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
leukemia	NN	leukemia	leukemia	leukemia	Y	O
.	.	.	.	.	N	O

Rare	JJ	rare	rare	rare	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
hepatosplenic	JJ	hepatosplenic	hepatosplenic	hepatosplen	N	B-AdverseReaction
T	NNP	t	t	t	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
HSTCL	NNP	hstcl	hstcl	hstcl	N	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocking	VBG	blocking	blocking	block	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
rare	JJ	rare	rare	rare	N	B-AdverseReaction
type	NN	type	type	type	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
T	NNP	t	t	t	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
a	DT	a	a	a	N	O
very	RB	very	very	veri	N	O
aggressive	JJ	aggressive	aggressive	aggress	N	O
disease	NN	disease	disease	diseas	N	O
course	NN	course	course	cours	N	O
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
usually	RB	usually	usually	usual	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Nearly	RB	nearly	nearly	nearli	N	O
all	DT	all	all	all	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reported	VBN	reported	reported	report	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
associated	VBN	associated	associated	associ	N	O
cases	NNS	cases	case	case	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
or	CC	or	or	or	N	O
ulcerative	JJ	ulcerative	ulcerative	ulcer	N	O
colitis	NN	colitis	colitis	coliti	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
were	VBD	were	were	were	N	O
in	IN	in	in	in	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
and	CC	and	and	and	N	O
young	JJ	young	young	young	N	O
adult	NN	adult	adult	adult	N	O
males	NNS	males	male	male	N	O
.	.	.	.	.	N	O

Almost	RB	almost	almost	almost	N	O
all	PDT	all	all	all	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
received	VBN	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
azathioprine	NN	azathioprine	azathioprine	azathioprin	N	O
(	(	(	(	(	N	O
AZA	NNP	aza	aza	aza	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
mercaptopurine	NN	mercaptopurine	mercaptopurine	mercaptopurin	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
MP	NN	mp	mp	mp	N	O
)	)	)	)	)	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
at	IN	at	at	at	N	O
or	CC	or	or	or	N	O
prior	VB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
diagnosis	VB	diagnosis	diagnosis	diagnosi	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
for	IN	for	for	for	N	O
hepatosplenic	JJ	hepatosplenic	hepatosplenic	hepatosplen	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
cannot	VBP	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
excluded	VBN	excluded	excluded	exclud	N	O
.	.	.	.	.	N	O

Melanoma	NNP	melanoma	melanoma	melanoma	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocking	VBG	blocking	blocking	block	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
formulation	NN	formulation	formulation	formul	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
.	.	.	.	.	N	O

Merkel	NNP	merkel	merkel	merkel	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocking	VBG	blocking	blocking	block	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

Periodic	JJ	periodic	periodic	period	N	O
skin	NN	skin	skin	skin	N	O
examination	NN	examination	examination	examin	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
skin	JJ	skin	skin	skin	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Wegener	NNP	wegener	wegener	wegen	N	O
's	POS	's	's	's	N	O
granulomatosis	NN	granulomatosis	granulomatosis	granulomatosi	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
cyclophosphamide	NN	cyclophosphamide	cyclophosphamide	cyclophosphamid	N	O
)	)	)	)	)	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
portion	NN	portion	portion	portion	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
group	NN	group	group	group	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
an	DT	an	an	an	N	O
exploratory	JJ	exploratory	exploratory	exploratori	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
formulation	NN	formulation	formulation	formul	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
persistent	NN	persistent	persistent	persist	N	O
asthma	NN	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
more	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
reported	VBN	reported	reported	report	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
control	NN	control	control	control	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
portion	NN	portion	portion	portion	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
RA	NNP	ra	ra	ra	Y	O
for	IN	for	for	for	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
and	CC	and	and	and	N	O
NMSC	NNP	nmsc	nmsc	nmsc	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
-	:	-	-	-	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	NN	up	up	up	N	O
was	VBD	was	wa	wa	N	O
0.56	CD	0.56	0.56	0.56	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
0.01	CD	0.01	0.01	0.01	N	O
,	,	,	,	,	N	O
3.11	CD	3.11	3.11	3.11	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
group	NN	group	group	group	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
0.00	CD	0.00	0.00	0.00	N	O
,	,	,	,	,	N	O
3.79	CD	3.79	3.79	3.79	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Congestive	JJ	congestive	congestive	congest	N	O
Heart	NNP	heart	heart	heart	N	O
Failure	NN	failure	failure	failur	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
congestive	JJ	congestive	congestive	congest	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
CHF	NNP	chf	chf	chf	N	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
new	JJ	new	new	new	N	B-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
CHF	NNP	chf	chf	chf	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
several	JJ	several	several	sever	N	O
exploratory	JJ	exploratory	exploratory	exploratori	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
CHF	NNP	chf	chf	chf	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
greater	JJR	greater	greater	greater	N	O
proportions	NNS	proportions	proportion	proport	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
CHF	NNP	chf	chf	chf	N	B-AdverseReaction
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	I-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
mortality	NN	mortality	mortality	mortal	N	I-AdverseReaction
.	.	.	.	.	N	O

SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
CHF	NNP	chf	chf	chf	N	O
and	CC	and	and	and	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CHF	NNP	chf	chf	chf	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
decision	NN	decision	decision	decis	N	O
is	VBZ	is	is	is	N	O
made	VBN	made	made	made	N	O
to	TO	to	to	to	N	O
administer	VB	administer	administer	administ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
to	TO	to	to	to	N	O
RA	NNP	ra	ra	ra	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CHF	NNP	chf	chf	chf	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
CHF	NNP	chf	chf	chf	N	O
appear	VBP	appear	appear	appear	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Demyelinating	VBG	demyelinating	demyelinating	demyelin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
rare	JJ	rare	rare	rare	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	B-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
or	CC	or	or	or	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
central	JJ	central	central	central	N	I-AdverseReaction
nervous	JJ	nervous	nervous	nervou	Y	I-AdverseReaction
system	NN	system	system	system	N	I-AdverseReaction
(	(	(	(	(	N	O
CNS	NNP	cns	cns	cn	N	I-AdverseReaction
)	)	)	)	)	N	O
demyelinating	VBG	demyelinating	demyelinating	demyelin	N	I-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
multiple	JJ	multiple	multiple	multipl	N	B-AdverseReaction
sclerosis	NN	sclerosis	sclerosis	sclerosi	N	I-AdverseReaction
(	(	(	(	(	N	O
MS	NNP	ms	m	ms	Y	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
demyelinating	NN	demyelinating	demyelinating	demyelin	N	I-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
central	JJ	central	central	central	N	B-AdverseReaction
demyelination	NN	demyelination	demyelination	demyelin	Y	I-AdverseReaction
,	,	,	,	,	N	O
MS	NNP	ms	m	ms	Y	B-AdverseReaction
,	,	,	,	,	N	O
optic	JJ	optic	optic	optic	N	B-AdverseReaction
neuritis	NN	neuritis	neuritis	neuriti	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
demyelinating	NN	demyelinating	demyelinating	demyelin	N	I-AdverseReaction
polyneuropathy	NNS	polyneuropathy	polyneuropathy	polyneuropathi	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
rarely	RB	rarely	rarely	rare	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
formulation	NN	formulation	formulation	formul	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
.	.	.	.	.	N	O

Prescribers	NNS	prescribers	prescribers	prescrib	N	O
should	MD	should	should	should	N	O
exercise	VB	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
considering	VBG	considering	considering	consid	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
central	JJ	central	central	central	N	O
or	CC	or	or	or	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
demyelinating	VBG	demyelinating	demyelinating	demyelin	N	O
disorders	NNS	disorders	disorder	disord	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
if	IN	if	if	if	N	O
these	DT	these	these	these	N	O
disorders	NNS	disorders	disorder	disord	N	O
develop	VBP	develop	develop	develop	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Abatacept	NNP	abatacept	abatacept	abatacept	N	O

In	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
and	CC	and	and	and	N	O
abatacept	NN	abatacept	abatacept	abatacept	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
infections	NNS	infections	infection	infect	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
alone	RB	alone	alone	alon	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
alone	RB	alone	alone	alon	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
demonstrated	VBN	demonstrated	demonstrated	demonstr	N	O
improved	JJ	improved	improved	improv	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
RA	NNP	ra	ra	ra	Y	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
including	VBG	including	including	includ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
and	CC	and	and	and	N	O
abatacept	NN	abatacept	abatacept	abatacept	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Anakinra	NNP	anakinra	anakinra	anakinra	N	O

Concurrent	JJ	concurrent	concurrent	concurr	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
anakinra	NN	anakinra	anakinra	anakinra	N	O
(	(	(	(	(	N	O
an	DT	an	an	an	N	O
interleukin	NN	interleukin	interleukin	interleukin	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
antagonist	NN	antagonist	antagonist	antagonist	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
another	DT	another	another	anoth	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
portion	NN	portion	portion	portion	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	O
additional	JJ	additional	additional	addit	N	O
benefits	NNS	benefits	benefit	benefit	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
anakinra	NN	anakinra	anakinra	anakinra	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Switching	VBG	switching	switching	switch	N	O
Between	NNP	between	between	between	N	O
Biological	NNP	biological	biological	biolog	N	O
Disease	NNP	disease	disease	diseas	N	O
Modifying	NNP	modifying	modifying	modifi	N	O
Antirheumatic	NNP	antirheumatic	antirheumatic	antirheumat	N	O
Drugs	NNP	drugs	drug	drug	N	O
(	(	(	(	(	N	O
DMARDs	NNP	dmards	dmards	dmard	N	O
)	)	)	)	)	N	O

Care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
when	WRB	when	when	when	N	O
switching	VBG	switching	switching	switch	N	O
from	IN	from	from	from	N	O
one	CD	one	one	one	N	O
biologic	JJ	biologic	biologic	biolog	N	O
product	NN	product	product	product	N	O
to	TO	to	to	to	N	O
another	DT	another	another	anoth	N	O
biologic	NN	biologic	biologic	biolog	N	O
product	NN	product	product	product	N	O
since	IN	since	since	sinc	N	O
overlapping	VBG	overlapping	overlapping	overlap	N	O
biological	JJ	biological	biological	biolog	N	O
activity	NN	activity	activity	activ	N	O
may	MD	may	may	may	N	O
further	RBR	further	further	further	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Cytopenias	NNP	cytopenias	cytopenia	cytopenia	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
post	VBN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
aplastic	JJ	aplastic	aplastic	aplast	N	B-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NNS	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
exercised	VBN	exercised	exercised	exercis	N	O
when	WRB	when	when	when	N	O
using	VBG	using	using	use	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
or	CC	or	or	or	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
significant	JJ	significant	significant	signific	N	O
cytopenias	NNS	cytopenias	cytopenia	cytopenia	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Vaccinations	NNP	vaccinations	vaccination	vaccin	N	O
Therapeutic	NNP	therapeutic	therapeutic	therapeut	N	O
Infectious	NNP	infectious	infectious	infecti	N	O
Agents	NNS	agents	agent	agent	N	O

Live	JJ	live	live	live	N	O
Vaccines	NNS	vaccines	vaccine	vaccin	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
may	MD	may	may	may	N	O
receive	VB	receive	receive	receiv	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
,	,	,	,	,	N	O
except	IN	except	except	except	N	O
for	IN	for	for	for	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
TNF	NN	tnf	tnf	tnf	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
limited	VBN	limited	limited	limit	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
live	VB	live	live	live	N	O
vaccination	NN	vaccination	vaccination	vaccin	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
secondary	JJ	secondary	secondary	secondari	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
by	IN	by	by	by	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
could	MD	could	could	could	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
Infectious	NNP	infectious	infectious	infecti	N	O
Agents	NNS	agents	agent	agent	N	O

Other	JJ	other	other	other	N	O
uses	NNS	uses	us	use	N	O
of	IN	of	of	of	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
infectious	JJ	infectious	infectious	infecti	N	O
agents	NNS	agents	agent	agent	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
live	JJ	live	live	live	N	O
attenuated	VBN	attenuated	attenuated	attenu	N	O
bacteria	NNS	bacteria	bacteria	bacteria	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
BCG	NNP	bcg	bcg	bcg	N	O
bladder	NN	bladder	bladder	bladder	N	O
instillation	NN	instillation	instillation	instil	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
cancer	NN	cancer	cancer	cancer	Y	O
)	)	)	)	)	N	O
could	MD	could	could	could	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
that	IN	that	that	that	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
infectious	JJ	infectious	infectious	infecti	N	O
agents	NNS	agents	agent	agent	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
concurrently	RB	concurrently	concurrently	concurr	N	O
with	IN	with	with	with	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
experience	NN	experience	experience	experi	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
systemic	JJ	systemic	systemic	system	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
following	VBG	following	following	follow	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
formulation	NN	formulation	formulation	formul	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
golimumab	NN	golimumab	golimumab	golimumab	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
an	DT	an	an	an	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	O
allergic	JJ	allergic	allergic	allerg	N	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	NNS	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
SIMPONI	NNP	simponi	simponi	simponi	N	O
ARIA	NNP	aria	aria	aria	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
instituted	VBN	instituted	instituted	institut	N	O
.	.	.	.	.	N	O

